Yes, the dose can and should be increased
For mood instability, quetiapine 50 mg daily is substantially below the therapeutic range, and dose escalation is both appropriate and necessary after two weeks without adequate response. Two weeks at a subtherapeutic dose is sufficient time to assess tolerability and proceed with titration.
Recommended Dose Escalation Strategy
Based on FDA labeling and clinical guidelines, the target therapeutic dose depends on the specific indication:
For Bipolar Mania (most likely given "mood instability"):
- Current dose (50 mg) is far below therapeutic range
- Target dose: 400-800 mg/day 1
- Recommended titration schedule 1:
- Day 1: 100 mg total (divided twice daily)
- Day 2: 200 mg total (divided twice daily)
- Day 3: 300 mg total (divided twice daily)
- Day 4: 400 mg total (divided twice daily)
- Further adjustments up to 800 mg/day by Day 6 in increments ≤200 mg/day
For Bipolar Depression:
- Target dose: 300 mg/day (given once daily at bedtime) 1
- Titration: 50 mg → 100 mg → 200 mg → 300 mg over 4 days
Key Clinical Considerations
The 50 mg dose is essentially a "test dose" used to assess tolerability, not a therapeutic dose for mood disorders. Multiple studies confirm that effective doses for acute mania average 575-600 mg/day among responders 2. Research demonstrates that rapid dose escalation to 400 mg within 2-5 days is safe and well-tolerated in acute settings 3, 4.
Important Caveats:
- Elderly or frail patients: Start lower (25 mg/day) and increase more gradually in 25-50 mg increments 1
- Hepatic impairment: Start 25 mg/day, increase by 25-50 mg/day as tolerated 1
- Monitor for: Orthostatic hypotension, sedation, dizziness (especially during titration) 5
Common Pitfall to Avoid:
Do not remain at subtherapeutic doses (50-200 mg) for mood disorders. While low-dose quetiapine (25-100 mg) is sometimes used off-label for insomnia or anxiety, this is inadequate for treating bipolar disorder. There is even concern that low doses may worsen mania through differential receptor antagonism (greater 5HT2A blockade relative to D2 at low doses) 6. The evidence for off-label low-dose use is weak and not supported by confirmatory trials 7.
Proceed with dose escalation now—the patient has been undertreated for two weeks.